ACTUATE THERAPEUTICS, INC. (ACTU)

Actuate Therapeutics is a Fort Worth-based biopharmaceutical company betting on a small set of cancer drugs. The company is early-stage—think clinical trials and R&D, not yet revenue from approved treatments—and is taking aim at hard-to-treat solid tumors and pediatric cancers where good options are scarce.

The company’s main engine is elraglusib injection, a glycogen synthase kinase-3 (GSK-3) inhibitor. This is a protein the company believes can slow or stop certain cancers from growing. Elraglusib is currently in Phase 2 trials for metastatic pancreatic ductal adenocarcinoma, one of the deadliest cancers—five-year survival rates are in the single digits. The company is also running an earlier Phase 1/2 trial of elraglusib for pediatric cancers including Ewing sarcoma, neuroblastoma, and pediatric leukemias. No drug has yet reached the finish line of FDA approval.

Actuate went public via reverse merger in August 2024 and trades on NASDAQ. The company has no product revenue. It burns cash on research and development, regulatory work, and the overhead of being a public company. Like most clinical-stage biotech, the business model is not yet a business—it is an option on the success of its pipeline and the science behind it.

The upside case is straightforward: if elraglusib works in trials and gains approval, it could become a revenue-generating asset in a category where unmet need is enormous. The downside is no less simple: development fails, trials miss, regulators say no, or a better competitor gets there first. Biotech is binary. Actuate’s SEC filings, including its 10-K (CIK 1652935), detail its clinical trial designs, burn rate, and the intellectual property around its GSK-3 approach. Investors in early-stage biotech should be comfortable with the possibility that this money is gone if the science doesn’t pan out.

Main programs in development:

• Elraglusib (metastatic pancreatic cancer) — Phase 2 trial ongoing
• Elraglusib (pediatric solid tumors) — Phase 1/2 trial for Ewing sarcoma, neuroblastoma, and leukemias